<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <nonSort>Stem</nonSort>
    <title>ming the Superbug Tide</title>
    <subTitle>Just A Few Dollars More</subTitle>
  </titleInfo>
  <name type="corporate">
    <namePart>Organización de Cooperación y Desarrollo Económico</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="marc">technical report</genre>
  <originInfo>
    <place>
      <placeTerm type="text">París</placeTerm>
    </place>
    <publisher>OECD Publishing</publisher>
    <dateIssued>2018</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <internetMediaType>pdf</internetMediaType>
    <extent>220 p. ; 1 documento PDF</extent>
  </physicalDescription>
  <abstract>Antimicrobial resistance (AMR) is a large and growing problem with the potential for enormous health and economic consequences, globally. As such, AMR has become a central issue at the top of the public health agenda of OECD countries and beyond. In this report, OECD used advanced techniques, including machine learning, ensemble modelling and a microsimulation model, to provide support for policy action in the human health sector. AMR rates are high and are projected to grow further, particularly for second- and third-line antibiotics, and if no effective action is taken this is forecasted to produce a significant health and economic burden in OECD and EU28 countries. This burden can be addressed by implementing effective public health initiatives. This report reviews policies currently in place in high-income countries and identifies a set of ‘best buys’ to tackle AMR that, if scaled up at the national level, would provide an affordable and cost-effective instrument in the fight against AMR</abstract>
  <targetAudience authority="marctarget">specialized</targetAudience>
  <note type="statement of responsibility">OECD</note>
  <subject authority="">
    <topic>Sanidad digital</topic>
  </subject>
  <subject>
    <topic>antimicrobial resistence</topic>
  </subject>
  <subject>
    <topic>machine learning</topic>
  </subject>
  <relatedItem type="series">
    <titleInfo>
      <title>OECD Health Policy Studies</title>
    </titleInfo>
  </relatedItem>
  <relatedItem>
    <internetMediaType>pdf</internetMediaType>
  </relatedItem>
  <identifier type="isbn">978-92-64-30759-9</identifier>
  <identifier type="uri">https://doi.org/10.1787/9789264307599-en</identifier>
  <location>
    <url displayLabel="Acceso al documento">https://doi.org/10.1787/9789264307599-en</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">ES-MaONT</recordContentSource>
    <recordCreationDate encoding="marc">181126</recordCreationDate>
    <recordChangeDate encoding="iso8601">20220207171830.0</recordChangeDate>
    <recordIdentifier source="ES-MaONT">00004808</recordIdentifier>
  </recordInfo>
</mods>
